MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

We analysed the prognostic significance of minimal residual disease (MRD) level in adult patients with acute myeloid leukemia (AML) treated in the randomized gemtuzumab ozogamicin (GO) ALFA-0701 trial.

Bibliographic Details
Main Authors:	Lambert, Juliette, Lambert, Jérôme, Nibourel, Olivier, Pautas, Cécile, Hayette, Sandrine, Cayuela, Jean-Michel, Terré, Christine, Rousselot, Philippe, Dombret, Hervé, Chevret, Sylvie, Preudhomme, Claude, Castaigne, Sylvie, Renneville, Aline
Format:	Online
Language:	English
Published:	Impact Journals LLC 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171629/

Similar Items

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
by: Renneville, Aline, et al.
Published: (2014)

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
by: Rosen, David B., et al.
Published: (2013)

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia
by: Bibault, Jean-Emmanuel, et al.
Published: (2015)

Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization
by: Jager, Eva, et al.
Published: (2011)

Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin
by: Kurimoto, M, et al.
Published: (2013)

Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
by: Jawad, Mays, et al.
Published: (2012)

Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia
by: AZUMA, YOSHIKO, et al.
Published: (2016)

Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013)
by: de Witte, Theo, et al.
Published: (2015)

Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg®) in children with relapsed/refractory myeloid leukemia
by: Brethon, Benoit, et al.
Published: (2006)

Spontaneous remission in three cases of AML M5 with NPM1 mutation
by: Camus, Vincent, et al.
Published: (2015)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
by: Pastore, Friederike, et al.
Published: (2014)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
by: Webersinke, G, et al.
Published: (2014)

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia
by: Kayser, S, et al.
Published: (2016)

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
by: Schönefeldt, C, et al.
Published: (2013)

Mutations in cell elongation genes mreB, mrdA and mrdB suppress the shape defect of RodZ-deficient cells
by: Shiomi, Daisuke, et al.
Published: (2013)

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association
by: Debarri, Houria, et al.
Published: (2015)

Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis
by: Chen, Chien-Yuan, et al.
Published: (2013)

An intensive approach to treatment for older patients with relapsed isolated NPM1 mutated AML
by: Dukka, Srivasavi, et al.
Published: (2015)

New Quantitative Method to Identify NPM1 Mutations in Acute Myeloid Leukaemia
by: Huet, Sarah, et al.
Published: (2013)

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
by: Cluzeau, Thomas, et al.
Published: (2012)

Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy
by: van den Ancker, Willemijn, et al.
Published: (2013)

Peripheral Blood WT1 Expression Predicts Relapse in AML Patients Undergoing Allogeneic Stem Cell Transplantation
by: Malagola, Michele, et al.
Published: (2014)

Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis
by: McDuff, Fiona Kate Elizabeth, et al.
Published: (2011)

Assessing impediments to NPM change
by: Peter, Steane, et al.
Published: (2015)

The value of molecular stratification for CEBPA DM and NPM1 MUT FLT3 WT genotypes in older patients with acute myeloid leukaemia
by: Dickson, Glenda J., et al.
Published: (2015)

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
by: Nagafuji, Koji, et al.
Published: (2013)

Function of homo- and hetero-oligomers of human nucleoplasmin/nucleophosmin family proteins NPM1, NPM2 and NPM3 during sperm chromatin remodeling
by: Okuwaki, Mitsuru, et al.
Published: (2012)

AML cells carrying NPM1 mutation are resistant to nucleophosmin displacement from nucleoli caused by the G-quadruplex ligand TmPyP4
by: De Cola, A, et al.
Published: (2014)

The NPM agenda in small developing countries
by: Desmond, Uelese Amosa
Published: (2008)

Inotuzumab Ozogamicin Murine Analog–Mediated B-Cell Depletion Reduces Anti-islet Allo- and Autoimmune Responses
by: Carvello, Michele, et al.
Published: (2012)

Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients
by: Capria, Saveria, et al.
Published: (2012)

Household Risk Management in Senegal
by: De Vreyer, Philippe, et al.
Published: (2013)

The Wilms Tumor-1 (WT1) rs16754 polymorphism is a prognostic factor in acute myeloid leukemia (AML): a meta-analysis
by: Long, Jianting, et al.
Published: (2016)

Immunophenotypic Characterisation And Evaluation Of Minimal Residual Disease (Mrd) In Acute Leukaemia Patients In Sarawak By Flow Cytometry
by: Mohamad Razif, Othman
Published: (2013)

Highly sensitive MRD tests for ALL based on the IKZF1 Δ3–6 microdeletion
by: Venn, N C, et al.
Published: (2012)

Comparison of microRNA expression in hippocampus and the marginal division (MrD) of the neostriatum in rats
by: Shu, Si Yun, et al.
Published: (2013)

Evolutionary Conservation of the Ribosomal Biogenesis Factor Rbm19/Mrd1: Implications for Function
by: Kallberg, Yvonne, et al.
Published: (2012)

Multiple RNA interactions position Mrd1 at the site of the small subunit pseudoknot within the 90S pre-ribosome
by: Segerstolpe, Åsa, et al.
Published: (2013)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
by: Othus, Megan, et al.
Published: (2016)

Low PKCa expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome
by: Milani, Gloria, et al.
Published: (2014)